Top

Published in:

01-08-2018 | Literatur kommentiert

Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC

Authors: Almut Dutz, Prof. Dr. Esther G. C. Troost, PD Dr. Steffen Löck

Published in: Strahlentherapie und Onkologie | Issue 8/2018

Auszug

Inoperable und lokal fortgeschrittene nicht-kleinzellige Bronchialkarzinome (NSCLC) werden standardgemäß mit einer simultanen Radiochemotherapie behandelt. Die Bestrahlung erfolgt dabei als intensitätsmodulierte Photonentherapie (IMRT). Planungsstudien zu Protonentherapie mit passiver Feldformung (PSPT) zeigten eine deutlich geringere Strahlenbelastung des gesunden Lungengewebes im Vergleich zur IMRT [1]. In dieser Arbeit untersuchten die Autoren die Hypothese, dass die Lungentoxizität (Strahlenpneumonitis, RP) nach PSPT geringer ist, ohne die Tumorkontrolle zu gefährden. …

Roelofs E, Engelsman M, Rasch C et al (2012) Results of a Multicentric in Silico Clinical Trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 7:165–176CrossRefPubMed

Higgins KA, O’Connell K, Liu Y et al (2017) National Cancer Database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 97:128–137CrossRefPubMed

Wink KCJ, Roelofs E, Charles SB II et al (2018) Photons, protons or carbon ions for stage I non-small cell lung cancer: results of the multicentric ROCOCO in silico study. Radiother Oncol. https://doi.org/10.1016/j.radonc.2018.02.024 PubMedCrossRef

Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199CrossRefPubMedPubMedCentral

Senan S, Brade A, Wang LH et al (2016) PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:953–962CrossRefPubMed

Kong F, Ten Haken RK, Schipper M et al (2017) Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol 3:1358–1365CrossRefPubMedPubMedCentral

Glimelius B, Montelius A (2007) Proton beam therapy – do we need the randomised trials and can we do them? Radiother Oncol 83:105–109CrossRefPubMed

Bentzen SM (2008) Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol 86:142–147CrossRefPubMedPubMedCentral

Goitein M, Cox JD (2008) Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 26:175–176CrossRefPubMed

10.

Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M (2013) Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 107:267–273CrossRefPubMed

11.

Lühr A, von Neubeck C, Krause M, Troost EGC (2018) Relative biological effectiveness in proton beam therapy – current knowledge and future challenges. Clin Transl Radiat Oncol 9:35–41CrossRefPubMedPubMedCentral

12.

Kadane JB, Seidenfeld T (1990) Randomization in a bayesian perspective. J Stat Plan Inference 25:329–345CrossRef

13.

Cheng Y, Shen Y (2005) Bayesian adaptive designs for clinical trials. Biometrika 92:633–646CrossRef

14.

Yin G, Lam CK, Shi H (2017) Bayesian randomized clinical trials: from fixed to adaptive design. Contemp Clin Trials 59:77–86CrossRefPubMed

15.

Hoffmann AL, Troost EGC, Huizenga H, Kaanders JHAM, Bussink J (2012) Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial. Int J Radiat Oncol Biol Phys 83:1596–1602CrossRefPubMed

16.

Kesarwala AH, Ko CJ, Ning H et al (2015) Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer 16:237–244CrossRefPubMed

17.

Register SP, Zhang X, Mohan R, Chang JY (2011) Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 80:1015–1022CrossRefPubMed

18.

Zhang X, Li Y, Pan X et al (2010) Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 77:357–366CrossRefPubMed

19.

Chang JY, Zhang X, Knopf A et al (2017) Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys 99:41–50CrossRefPubMed

20.

Jakobi A, Perrin R, Knopf A, Richter C (2018) Feasibility of proton pencil beam scanning treatment of free-breathing lung cancer patients. Acta Oncol 57:203–210CrossRefPubMed

21.

Grassberger C, Dowdell S, Sharp G, Paganetti H (2015) Motion mitigation for lung cancer patients treated with active scanning proton therapy. Med Phys 42:2462–2469CrossRefPubMedPubMedCentral

22.

Zschaeck S, Simon M, Löck S et al (2016) PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. Trials 17:543CrossRefPubMedPubMedCentral

Title: Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC
Authors: Almut Dutz
Prof. Dr. Esther G. C. Troost
PD Dr. Steffen Löck
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 8/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1321-3

At a glance: The STEP trials

Springer Medicine

Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC

Auszug

At a glance: The STEP trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 8/2018

Socioeconomic status and quality of life in patients with locally advanced head and neck cancer

Spatial orientation of coronary arteries and its implication for breast and thoracic radiotherapy—proposing “coronary strip” as a new organ at risk

Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy

Inclusion of dosimetric data as covariates in toxicity-related radiogenomic studies

Lokoregionale Tiefenhyperthermie verbessert das krankheitsspezifische Gesamtüberleben in Kombination mit einer neoadjuvanten Chemotherapie bei Hochrisiko-Weichteilsarkomen

Radiation-induced carotid artery lesions